Paper Review Records
All Paper Review Records
30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
409
days
Untargeted Metabolomics of Dried Blood Spots for Inherited Metabolic Disorder Classification
Authors
Jan‐Clemens Cremer; Lorenz Waltl; Viktorija Juric; Jakob Koch; Sabine Scholl‐Bürgi; Daniela Karall; Johannes Zschocke; Markus A. KellerShow moreShow less
Affiliations
1. Institute of Human Genetics, Medical University of Innsbruck Innsbruck Austria; 2. Department of Paediatrics I (Inherited Metabolic Disorders) Medical University of Innsbruck Innsbruck AustriaShow moreShow less
84
days
Bringing Untargeted Metabolomics to the Clinic: Real‐World Data and Implementation for Screening of Inherited Metabolic Diseases
Authors
D. Augustijn; R. Bonte; M. C. Hagemeijer; J. Bierau; E. H. Jacobs; C. J. Klein‐de Ronde; E. van der Star; D. Y. van Haaften‐Visser; N. C. Peltenburg‐de Jong; C. Debuy; M. van Dijk; D. Vos; G. J. G. Ruijter; S. M. I. GoordenShow moreShow less
Affiliations
1. Centre of Lysosomal and Metabolic Diseases, Department of Clinical Genetics Erasmus Medical Centre Rotterdam the Netherlands; 2. Department of Clinical Chemistry Erasmus MC Rotterdam the Netherlands; 3. Centre of Lysosomal and Metabolic Diseases, Department of Paediatrics Erasmus Medical Centre Rotterdam the Netherlands; 4. Centre of Lysosomal and Metabolic Diseases, Department of Internal Medicine Erasmus Medical Centre Rotterdam the Netherlands; 5. Laboratory Genetic Metabolic Diseases, Department of Laboratory Medicine Amsterdam University Medical Centre Amsterdam the NetherlandsShow moreShow less
209
days
Migalastat Versus Enzyme Replacement Therapy in Treatment‐Naïve F abry Disease: Real‐World Evidence From the followME F abry Pathfinders Registry
Authors
Peter Nordbeck; Agnieszka Kopiec; Noemi Hummel; Vera Gielen; Biliana O. Veleva‐Rotse; Alasdair MacCullochShow moreShow less
Affiliations
1. University Hospital Würzburg Würzburg Germany; 2. Certara Krakow Poland; 3. Certara GmbH Lörrach Germany; 4. BioMarin UK Ltd London UK; 5. BioMarin Pharmaceutical Inc. Novato California USAShow moreShow less
145
days
Nucleic Acid Therapeutics in Rare Disease: From Precision Medicine to Programmable Platforms
Authors
Tomasz Z. Tomkiewicz; Siyamini Sivananthan; Paul Gissen; Haiyan ZhouShow moreShow less
Affiliations
1. Genetics and Genomic Medicine Research and Teaching Department Great Ormond Street Institute of Child Health, University College London London UK; 2. NIHR Great Ormond Street Hospital Biomedical Research Centre London UKShow moreShow less
195
days
Thymidine Kinase 2 Deficiency in the Era of Approved Therapy: From Diagnosis to Evidence Across the Disease Spectrum
Authors
Paloma Martin‐Jimenez; Cristina Domínguez‐GonzálezShow moreShow less
Affiliations
1. Neuromuscular Diseases Unit, Neurology Department Hospital Universitario 12 de Octubre Madrid Spain; 2. Medical‐Surgical Sciences Research, Faculty of Medicine Complutense University Madrid Spain; 3. Mitochondrial and Neuromuscular Research Group ’12 de Octubre’ imas12 Research Institute Madrid Spain; 4. Biomedical Network Research Centre on Rare Diseases (CIBERER), Instituto de Salud Carlos III Madrid SpainShow moreShow less
83
days
Revisiting Inherited Metabolic Diseases ( IMDs ) Through the Lens of Selective Autophagy
Authors
Marianna Maddaluno; Laura Cinque; Viviana Cetrangolo; Chiara De LeonibusShow moreShow less
Affiliations
1. Telethon Institute of Genetics and Medicine (TIGEM) Pozzuoli Italy; 2. Department of Clinical Medicine and Surgery Federico II University Naples Italy; 3. Department of Precision Medicine University of Campania “Luigi Vanvitelli” Naples Italy; 4. Department of Health Sciences University of Basilicata Potenza ItalyShow moreShow less
FAQ
How long does JOURNAL OF INHERITED METABOLIC DISEASE take to review a manuscript?
As of 2026-11-17, CrushSCI has 30 complete review records for JOURNAL OF INHERITED METABOLIC DISEASE. The fastest paper went from submission to acceptance in 35 days (Consensus Guidelines for Diagnosis and Management of Pyruvate Dehydrogenase Complex Deficiency, received 2026-05-29, accepted 2026-07-03); the slowest took 409 days. The average is 157.6 days and the median is 145 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
